<Previous Article In Issue
Volume 2, Issue 2, June 2020, Pages 92 - 93
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
Authors
Mohamad Mohty1, *, 
, Florent Malard1, , Ali Bazarbachi2, 3
, Florent Malard1, , Ali Bazarbachi2, 31Sorbonne Universités, INSERM, Centre de Recherche Saint-Antoine (CRSA), Hematology Department, AP-HP, Saint Antoine Hospital, Paris, France
2Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
3Department of Anatomy, Cell Biology, and Physiological Sciences, American University of Beirut, Beirut, Lebanon
*Corresponding author. Email: mohamad.mohty@inserm.fr
Corresponding Author
Mohamad Mohty
Received 24 January 2020, Accepted 7 May 2020, Available Online 18 May 2020.
- DOI
- 10.2991/chi.d.200507.001How to use a DOI?
- Copyright
- © 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Download article (PDF)
View full text (HTML)
<Previous Article In Issue
Cite this article
TY - JOUR AU - Mohamad Mohty AU - Florent Malard AU - Ali Bazarbachi PY - 2020 DA - 2020/05/18 TI - Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better JO - Clinical Hematology International SP - 92 EP - 93 VL - 2 IS - 2 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.200507.001 DO - 10.2991/chi.d.200507.001 ID - Mohty2020 ER -